Kyowa Hakko Kirin Plans Overseas Expansion As Global Specialty Pharma
This article was originally published in PharmAsia News
Kyowa Hakko Kirin President Nobuo Hanai said the company’s mid-term management plan starting next year includes policies to expand overseas with their antibody KW-0761.
You may also be interested in...
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.